clinical-trial
-
Unpacking Wave's PRECISION-HD2 huntingtin-lowering trial announcement
10 min read
Wave Life Sciences announces that its antisense drug WVE-120102 has lowered mutant huntingtin protein in cerebrospinal fluid, but investors seem disappointed. Rather confusing – what do we know for sure?
-
Details emerge of first Huntington’s disease gene therapy clinical trial
8 min read
UniQure announces key details of its planned trial to assess the safety and ability of AMT-130 gene therapy to lower the problematic huntingtin protein using a ‘single-shot’ virus delivery system.
-
Advances on many fronts in the battle against the protein that causes Huntington's disease
11 min read
This fall sees exciting announcements from a number of companies focused on novel Huntingtin Lowering technologies, including Wave, PTC and Voyager
-
Disappointing news from LEGATO-HD trial of laquinimod in Huntington's disease
5 min read
The LEGATO-HD trial of laquinimod did not slow progression of Huntington's disease. Here's the lowdown.
-
Success! ASO drug reduces levels of mutant protein in Huntington's disease patients
11 min read
Amazing news from Ionis and Roche! HTTRx drug successfully lowers harmful huntingtin protein in spinal fluid
-
A new way of thinking about trials to prevent Huntington's disease
6 min read
Can we test drugs to delay or prevent the onset of Huntington's disease? New research suggests it's possible
-
Precision huntingtin-lowering drug trials target the mutant protein
10 min read
WAVE Life Sciences launches PRECISION clinical trial to suppress the mutant Huntington's disease protein
-
Update confirms Huntington's disease 'gene silencing' trial on track
10 min read
Ionis says its trial of HTTRx, intended to lower huntingtin protein, is fully recruited and plans to extend it
-
New study reveals a potential HD biomarker
8 min read
A potential HD biomarker has been uncovered in a recent clinical study
By Dr Leora Fox -
FDA approves a new drug for symptoms of Huntington's disease
4 min read
Deutetrabenazine becomes the first new drug in a decade licensed by the FDA for symptoms of Huntington's disease